Objective: To demonstrate that expectant observation of young infants with small adrenal masses would result in excellent event-free and overall survival. Background: Neuroblastoma is the most common malignant tumor in infants, and in young infants, 90% of neuroblastomas are located in the adrenal gland. Although surgical resection is standard therapy, multiple observations suggest that expectant observation could be a safe alternative for infants younger than 6 months who have small adrenal masses. Methods: A prospective study of infants younger than 6 months with small adrenal masses and no evidence of spreading beyond the primary tumor was performed at participating Children's Oncology Group institutions. Parents could choose observation or immediate surgical resection. Serial abdominal sonograms and urinary vanillylmandelic acid and homovanillic acid measurements were performed during a 90-week interval. Infants experiencing a 50% increase in the volume of the mass, urine catecholamine values, or an increase in the homovanillic acid to vanillylmandelic acid ratio greater than 2, were referred for surgical resection. Results: Eighty-seven eligible patients were enrolled: 83 elected observation and 4 chose immediate surgery. Sixteen observational patients ultimately had surgery; 8 had International Neuroblastoma Staging System stage 1 neuroblastoma, 2 had higher staged neuroblastoma (2B and 4S), 2 had low-grade adrenocortical neoplasm, 2 had adrenal hemorrhage, and 2 had extralobar pulmonary sequestration. The 2 patients with adrenocortical tumors were resected because of a more than 50% increase in tumor volume. The 3-year event-free survival for a neuroblastoma event was 97.7 ± 2.2% within the entire cohort of patients (n = 87). The 3-year overall survival was 100%, with a median follow-up of 3.2 years. Eighty-one percent of patients on the observation arm were spared resection. Conclusions: Expectant observation of infants younger than 6 months with small adrenal masses led to excellent event-free survival and overall survival while avoiding surgical intervention in a large majority of the patients.
N euroblastoma is the most common malignant tumor in infants. The majority of these are small, localized adrenal tumors at the time of diagnosis. 1 Surgical resection is the standard treatment modality, with excellent overall results. [2] [3] [4] [5] [6] [7] [8] Two lines of evidence suggest that expectant observation may decrease the need for resection, however. First, a high rate of spontaneous regression is observed in infants with neuroblastoma and several investigators have reported regression of localized prenatally diagnosed adrenal masses, [9] [10] [11] and there is considerable evidence for spontaneous regression of tumors detected through population screening programs for neuroblastoma. [12] [13] [14] [15] [16] Furthermore, several groups have reported the spontaneous regression of larger tumors that were observed after diagnostic biopsies or partial resections. 17, 18 In addition to these data supporting spontaneous regression, there is evidence that the morbidity and mortality associated with surgery may be greater than the risk of developing a tumor in an infant. Although no study has specifically investigated the risks of adrenal surgery in young infants, the available literature suggests that there are significant risks associated with the resection of adrenal and nonadrenal abdominal neuroblastoma tumors in infants younger than 1 year, with a trend toward a higher risk in younger infants. 5, 19, 20 Infants are also at a higher risk of anesthetic complications than are older children. 21, 22 The overall mortality rate for young infants undergoing adrenal surgery for tumor resection seems to be 2% or higher. 5, 23 Previous observation trials suggest that tumor sizes and characteristics, and certain patterns of urine catecholamine metabolite (vanillylmandelic acid and homovanillic acid) secretions, are associated with a benign pattern of behavior and an increased probability of spontaneous regression. 13, 15, 16, [24] [25] [26] We conducted a prospective trial of the expectant observation of infants with small adrenal tumors identified either prenatally or within the first 6 months of life. The key feature of this protocol was close sonographic monitoring of the tumor volume and catecholamine secretion with an increased frequency of surveillance in those infants whose tumors enlarged in volume, had increased levels of urine vanillylmandelic acid or homovanillic acid, or had an homovanillic acid to vanillylmandelic acid ratio of more than 2. 27 If these signs of tumor growth or dedifferentiation persisted, the patient was referred for a surgical resection. NCT00445718) that obtained institutional review board approval (localized or centralized) and opened the study. The study was opened to enrollment on July 9, 2001 , and reached accrual and was closed on January 8, 2010. Informed consent was given by the parent or legal guardian. The eligibility criteria were designed to select a group of infants with small adrenal masses without evidence of local extension beyond the gland or distant metastases, that is, International Neuroblastoma Staging System stage 1 tumors.
The specific eligibility criteria were (a) age 6 months or less on the date the mass was first identified, and the date of enrollment must be less than 120 days after the first imaging study identifying the mass, if identified postnatally, or the patient must be younger than 120 days if the first imaging study identifying the mass was prenatal; (b) a sonographically identified adrenal mass, which is 16 mL or less in volume (assuming an ellipsoid with volume V = (4/3)π (X/2)(Y/2)(Z/2), where X = maximum longitudinal diameter, Y = maximum transverse diameter, and Z = maximum anterior-posterior diameter), corresponding to a sphere with a diameter of 3.1 cm if solid or 65 mL or less in volume (corresponding to a sphere with a diameter of 5.0 cm) if the mass was at least 25% cystic and did not cross the midline; (c) disease limited to the adrenal gland as demonstrated by abdominal computerized tomography or magnetic resonance scan and MIBG (I 131 -meta-iodobenzylguanidine) scintiscan; and (d) no prior abdominal surgery or chemotherapy. In addition, a bone marrow biopsy was encouraged but not required. If such a biopsy was obtained, it was required that it be negative for tumor cells.
Treatment Protocol
At the time of enrollment, parents or legal guardians were offered 2 possible treatment plans: expectant observation or immediate surgical resection. For those patients on the expectant observation arm, abdominal sonograms were obtained at prescribed intervals during the 90-week observation period of the study (Table 1) . All ultrasonographic studies included imaging of the liver with a high-frequency linear transducer to ensure optimal detection of small parenchymal nodules. In addition, all patients underwent computerized tomography or magnetic resonance imaging of the abdomen at 6 and 42 weeks to ensure that there was no progression beyond the adrenal gland. With rare exceptions, imaging studies were reviewed centrally by the study radiologist (C.E.B.). Urinary samples were obtained at presentation and at the time of each subsequent ultrasonographic study and analyzed for vanillylmandelic acid and homovanillic acid, using gas chromatography/mass spectroscopy (Table 1) .
Expectant observation was terminated and the child was referred for surgical resection if the volume of the mass increased by 50% compared with the volume at the time of enrollment. If an increase in volume of the tumor was noted, but it was not of an adequate magnitude to mandate resection, then continued sonographic evaluation at 3-week intervals was performed until a stable volume was noted on 2 successive studies or the patient had surgery. After the mass had stabilized in volume on 2 consecutive 3-week studies, the Abdominal sonogram X X X X X X X X X UrineVMA/HV A X X X X X X X X X Abdominal CT/MRI X X X CT indicates computerized tomography; MRI, magnetic resonance imaging; VMA, vanillylmandelic acid; HVA, homovanillic acid. next sonogram/urine vanillylmandelic acid/homovanillic acid analysis was at a 6-week interval, and the following studies were at the regularly scheduled times based on the original entry date. Urinary catecholamine levels, vanillylmandelic acid and homovanillic acid, were obtained at presentation and at the time of each subsequent ultrasonographic study. If these metabolites showed an increase in value of greater than 50% above the initial baseline value (and the actual value was abnormal) or if the vanillylmandelic acid to homovanillic acid ratio decreased below 0.5 (and the actual homovanillic acid value was above normal), the time interval until the subsequent studies (sonograms and urine catecholamine sampling) was decreased to 3 weeks. Similar increased surveillance took place if the vanillylmandelic acid or homovanillic acid levels, having decreased to a new nadir level below the value at entry, subsequently increased 50% above the nadir, assuming that this value was above the upper limit of normal. If the elevated value did not return to the baseline/nadir value (or the upper limit of normal, whichever was greater) within 12 weeks or the vanillylmandelic acid to homovanillic acid ratio did not rise above 0.5 within 6 weeks, the patient came off-observation and surgery was recommended without regard to the tumor volume. If there was no evidence of an adrenal mass on imaging at this time, it was recommended that the patient undergo computerized tomography or magnetic resonance imaging of the neck, chest, and abdomen, and a bone marrow aspiration/biopsy and bone scan to rule out occult disseminated disease. On the contrary, if the catecholamine values returned to the baseline, subsequent studies took place 6 weeks later and then at the regularly scheduled times. These off-observation criteria are listed in Table 2 .
If there was a residual adrenal mass larger than 2 mL in volume (a 1.6-cm sphere) at the end of the observation period, it was recommended that the mass be resected. If a patient completed the 90-week observation period without triggering a resection due to an increase in tumor volume or catecholamine values, yet the vanillylmandelic acid and/or homovanillic acid values remained elevated, any persistent adrenal mass was resected regardless of its volume. For patients whose parents opted for immediate surgery, data were collected regarding the operative report, pathology report, and initial diagnostic studies.
Statistical Considerations
There are an estimated 136 patients per year with a diagnosis of neuroblastoma prenatally or 6 months or younger at the Children's Oncology Group member institutions. On the basis of previous work, 6, 10 we estimated that 90% of the tumors were adrenal in location and 30% would be International Neuroblastoma Staging System stage 1. In addition, we estimated that approximately one third of families would consent to protocol therapy, for an annual accrual rate of 14 patients. The actual accrual rate was approximately 11 patients per year during the time of the study. Event-free survival and overall survival were estimated using the Kaplan-Meier method. For the purpose of this study, a neuroblastoma event was defined as the progression toward or recurrence of an International Neuroblastoma Staging System stage 2 or more neuroblastoma after resection. For event-free survival for a neuroblastoma event, time to event was defined as the time from study enrollment until the first occurrence of a neuroblastoma event, second malignancy, or death from any cause, or until the time of last contact, if no event occurred. Any malignancy event was defined as the occurrence of a neuroblastoma event or the finding of any non-neuroblastoma malignancy upon resection of the primary adrenal mass. For event-free survival for any malignant event, the time to event was defined as the time from study enrollment until the first occurrence of a neuroblastoma event, any malignancy event, second malignancy, or death from any cause, or until the time of last contact, if no event occurred. For the overall survival, death was the only event considered. In addition, the resection-free survival was estimated for those patients on the expectant observation arm, where the occurrence of a resection was the only event considered. The study was not designed or powered for subgroup comparisons of survival curves; log-rank tests were not performed, but 3-year estimates ± standard error have been presented.
Because this was a reduction in therapy study, sequential monitoring was performed to provide the early detection of a reduction in event-free survival compared with the excellent results of legacy studies in which surgical resection was the primary therapy for the patients with International Neuroblastoma Staging System stage 1. An early stopping rule was planned to halt the study if the 2-year event-free survival fell below an acceptable value of 95%. Sequential monitoring of the need for surgical resection was also performed, whereby the study would be stopped if the rate of resection exceeded 75%. Tests for proportions were based on the binomial distribution. The values of P < 0.05 were considered statistically significant.
RESULTS
A total of 97 infants were enrolled in the study, and 10 of these were subsequently determined to be ineligible for these reasons: enrolled after surgical resection (n = 5); the time interval was too long between diagnosis and enrollment (n = 3); and informed consent issues (n = 2). The remaining 87 eligible patients formed the analytical cohort for this article. Eighty-three of these patients were enrolled in the observation arm of the study, and 4 in the immediate surgery arm. For the observation arm, 56 patients completed observation and 27 discontinued observation (13 of whom were lost to follow-up during the 90-week observation period) ( Table 3) . Twenty-seven patients had a diagnosis prenatally or on the first day of life; for patients with a diagnosis beyond this time, the median age at diagnosis was 14 days. The median age at enrollment was 42 days. The male to female ratio was 2.1. Twenty-six percent of the patients had elevated urine catecholamine values at the time of enrollment, and 33% of the tumors were 25% or more cystic by volume. There was no significant correlation between the proportion of patients who completed the observation arm of the trial and the time of diagnosis (pre-or postnatal), sex, cystic or solid nature of the mass, or the urine catecholamine levels at the time of diagnosis (normal or elevated).
The vast majority of the patients who completed the observation arm had a decrease in the volume of the adrenal mass. Among these 56 patients, 27 (48%) had no residual masses, 13 (23%) had a mass larger than 0 but 1 mL or less, 8 (14%) had a mass larger than 1 but 2 mL or less, and 8 (14%) had a mass larger than 2 mL. Thus, 71% had a residual mass of 1 mL or less in volume (including those with no discernible masses) and 86% had a residual mass of 2 mL or less in volume. Fifty-four patients had vanillylmandelic acid determinations at the end of observation, 50 (93%) of these had normal levels. Fifty-six patients had homovanillic acid determinations at the end of observation, 53 (95%) of these had normal levels.
Twenty patients underwent resections: 4 went into the immediate surgery arm and 16 patients who were originally entered into the observation arm ultimately underwent a resection (Table 4) . Fifteen patients in the latter group had resections during the 90-week observation period, and 1 patient had surgery after completing the observation protocol. One of the 15 patients who had a resection during observation was lost to follow-up on the day of surgery-the tumor histology was consistent with adrenal hemorrhage. Among the 16 observation arm patients who eventually had surgery, 10 patients had neuroblastomas, 2 had low-grade adrenal cortical neoplasms, 2 had adrenal hemorrhages or hematomas, and 2 had extralobar pulmonary sequestrations. Nine of the patients with neuroblastoma had signs of tumor growth or progressive disease, and 1 patient underwent a resection at the request of his or her parents. Among the 9 patients with tumor growth or progression, 7 had International Neuroblastoma Staging System stage 1 disease (6 had surgery because of a >50% increase in tumor volume, and 1 because of a sustained increase in catecholamine secretion) and 2 patients had progressive disease [1 patient had liver involvement noted at the time of the first follow-up ultrasonography, this patient had stage 4S disease and was alive at 5.6 years follow-up; the second patient went to surgery because of a >50% increase in the volume of a mass and was found to have stage 2B disease (ipsilateral lymph node involvement), and this patient was lost to follow-up after 1.7 years without relapse or further progression]. All of the 9 patients with neuroblastoma with tumor growth and/or progression had solid rather than cystic tumors.
Thirteen patients were lost to follow-up during the 90-week observation period (Table 5 ). The mean observation period in this group was 342 days. Patient A had an elective resection of a mass after 491 days of follow-up and was found to have a resolving adrenal hemorrhage. The remaining patients were lost to follow-up before any known tumor resection. In 12 of the 13 patients, the residual tumor volume was less than 1 mL at the time of the last submitted sonographical evaluation. In the 12 patients for whom data were available, 10 patients had normal urine catecholamine metabolite values at their last evaluation.
For the overall cohort (n = 87), the 3-year event-free survival for a neuroblastoma event ± standard error was 97.7 ± 2.2%, the 3-year event-free survival for any malignant event was 95.3 ± 3.1%, and the 3-year overall survival was 100% (Fig. 1) . Note that the 2 low-grade adrenal cortical neoplasms and the 2 neuroblastoma progressions were the 4 events that were factored into the 3-year event-free survival for any malignant event rate, because the 2 adrenal hemorrhages/hematomas and the 2 extralobar pulmonary sequestrations were benign and not considered malignancies. However, 1 patient with a solid tumor who completed the 90-week observation period without requiring a resection died after 4 years because of end-stage renal disease due to a preexisting Joubert syndrome with a Dandy-Walker malformation. The patients without events had a median follow-up time of 3.2 years. Sixty-seven of the 83 (81%) observation patients were spared resection. The 3-year resection-free survival rate was 79.8 ± 6.0% (Fig. 2) . Of the 83 patients in the observation arm, the 3-year eventfree survival for a neuroblastoma event was 100% for patients with a cystic mass (n = 27) and 96.4 ± 3.4% for patients with a solid mass FIGURE 1. Event-free survival for a "neuroblastoma event", event-free survival for "any malignancy event", and overall survival for 87 eligible patients. The number of patients at risk for event at the start of years 3 and 6 appear along each curve. Note that the y-axis of the survival plots begins at 60%, not 0%.
(n = 56) and the 3-year resection-free survival was 88.6 ± 8.6% for patients with a cystic mass (n = 27) and 75.9 ± 7.6% for patients with a solid mass (n = 56).
DISCUSSION
Neuroblastoma is a clinically heterogeneous disease. In infants, it often presents as a localized adrenal mass. Although surgical resection is normally curative in these children, it can be associated with significant morbidity and mortality. It is known from several single-institution studies that many of these tumors will regress spontaneously. Our hypothesis was that expectant observation, with resection limited to those tumors that exhibited persistent growth, would result in excellent survival while sparing the majority of infants from the need for a surgical resection. The results of the study confirm this concept: the event-free survival for a neuroblastoma event, event-free survival for any malignant event, and overall survival were comparable with previous studies in which surgery, at times combined with chemotherapy, was used as the primary therapy for infants with stage 1 neuroblastoma. 2, 3, [6] [7] [8] 10, 11, 28 In fact, the 2 patients who had a progression beyond stage 1 had low-or intermediate-risk disease and did not require further treatment. Several studies have suggested that the burden of surgical treatment is greater than that of the disease in infants with localized neuroblastoma. 5, 8, 13, 20, 29 Given that four fifths of the patients in this study were spared surgery, this approach represents a significant improvement in the outcome for these children.
Our results are consistent with previous reports documenting the safety and effectiveness of expectant observation for localized infant neuroblastoma. Holgersen et al 9 reported spontaneous regression of adrenal masses detected on prenatal sonograms within the first 4 postnatal months. Similar results were obtained in a retrospective analysis of suprarenal masses detected either prenatally or in the first 120 days of life.
11 Japanese investigators have conducted several prospective trials of the expectant observation of presumed neuroblastoma tumors detected through mass screening for elevated urine vanillylmandelic acid or homovanillic acid levels at 6 months of age. [12] [13] [14] [15] [16] 30 These studies used relatively similar eligibility criteria including a tumor diameter of less than 5 cm, Evans stage I or II, a resectable mass without invasion of the spinal canal or involvement of the great vessels, and urine vanillylmandelic acid and homovanillic acid levels of less than 50 μg/mg of creatinine. The rate of completely spontaneous regression ranged from 59% to 70%, and there were no recurrences among the observed patients. These findings were further extended in a prospective cooperative trial by the German Society of Pediatric Oncology and Hematology, in which infants younger than 1 year, with biopsy-proven, MYCN nonamplified, stage 1, 2, or 3 neuroblastoma underwent expectant observation, unless a tumor resection was judged to be of low risk. 18 Forty-seven percent of these observed patients had some degree of regression; in 17%, it was complete, whereas 4% progressed to stage 4 disease.
In this study, we required a tumor diameter of 3.1 cm or less for the observation of solid masses and 5 cm for masses with more than 25% cystic character by volume. The larger size limit for the cystic masses was based on the identification of cystic tumors as a particularly benign subset of infant neuroblastomas. 26, 31, 32 The eventfree survival for a neuroblastoma event and resection-free survival between those patients with a cystic mass seem to be similar to that of patients with a solid mass despite allowing a larger volume at the diagnosis of the former group.
We report the first North American cooperative group trial of the expectant observation of solid tumors in infants. Although the rate at which patients were lost to follow-up was high, we argue that it is unlikely that the inclusion of these patients in the analysis would change the fundamental conclusions of our study. More than 90% of the lost to follow-up patients had tumor volumes of less than 1 mL at the time of their last follow-up, implying that these patients' tumors were unlikely to increase in size after being lost to follow-up.
This article supports the safety of the expectant observation of small adrenal masses in young infants with stable or decreasing urine vanillylmandelic acid and homovanillic acid. It is consistent with mounting evidence that size, stage, and catecholamine metabolite secretion patterns can be used to define a safe group for observation. A tumor diameter of less than 5 cm and International Neuroblastoma Staging System stage 1 or 2 have been demonstrated as safe criteria in multiple observational studies. [12] [13] [14] [15] [16] 30 An upper limit on catecholamine secretion levels has been used in many protocols, although it is not clear whether this adds safety or if it is simply a convenient way to exclude those children with tumors that are likely to grow rapidly and trigger a resection after a short period of observation. [12] [13] [14] [15] [16] 33 Although the bulk of the available data demonstrating spontaneous regression is from infants with a diagnosis during the first 6 months of life, there is sufficient evidence that observation could be safely extended to infants younger than 1 year with a standardized monitoring protocol. 17, 18, 34 Furthermore, although most neuroblastoma tumors arise within the adrenal gland in infants, statistical modeling suggests that the extra-adrenal subset of tumors have a higher probability of regression. 35 Expectant observation can be considered the standard therapy for infants who fulfill the eligibility requirements of this study: solid adrenal tumor of less than 3.1 cm (or cystic <5 cm), International Neuroblastoma Staging System stage 1, and younger than 6 months. We recommend extending these criteria to include all localized, noninfiltrative neuroblastoma tumors (corresponding to the International Neuroblastoma Risk Group Staging System stage L1 36 ) in infants younger than 1 year. This further reduction in standard therapy should be tested in a prospective clinical trial.
DISCUSSANT
DR. MICHAEL P. LAQUAGLIA (New York, NY): The authors are to be congratulated for completing this study in a cooperative group dominated by pediatricians and chemotherapy questions, especially in view of the nine year interval that this study remained open to accrual. They have essentially capitalized on an observation initially made by Harvey Cushing in 1927; that is, neuroblastomas can undergo spontaneous differentiation. And what they have done is defined, in a subset of patients, the conditions under which that observation can be used clinically.
This study is a phase II study of treatment reduction; that is, total elimination of surgery, even a biopsy, or any other intervention, with the institution of rigorous and evidence based stopping rules which include change in tumor size and patterns of urinary catecholamine secretion. It is the first such prospective study ever reported.
The study population was limited to infants and children with small, stage I tumors, who were six months of age or younger at the time of diagnosis. The bar for this study was high since previous cooperative group studies had reported close to 100% survival with surgery. The results indicate that this is a safe approach, with a three year overall survival of 100%, and an acceptable, event free survival of 95%.
There were no progressions to high risk neuroblastoma. And surgery was completely avoided in approximately 80% of babies. Although this was an ethical and well conceived protocol, I think the authors should explain further as to why a randomization was not included.
I also would note that the categorization of outcomes as neuroblastoma protocol events versus any malignancy events is somewhat complicated and confusing, and perhaps could be simplified. This is really directed toward the patients with the adrenocortical low grade tumors.
Finally, 11 patients were lost to follow-up; that is, they didn't have the 90-week prescribed follow-up for the protocol. The authors should describe how this affects their results.
Nevertheless, I believe this study will have a major impact on the future care of infants and newborns with small adrenal masses. More than that, however, the authors have laid the foundation for extending the use of an observational approach to larger subsets of children with neuroblastoma.
Older children with localized or loco-regional disease and favorable imaging and biologic factors can more readily be included in an observational arm based on these data. To put it in context, all these children presently receive chemotherapy and surgery and some in the past have even received radiation therapy, only to have significant and tragic late effects or secondary malignancies.
Dr. Nuchtern and his colleagues have provided scientific evidence and defined workable safety procedures that will allow other cohorts of patients to benefit from therapy reduction. And also, they have provided a springboard for further prospective studies along these lines.
The two questions I had were, in the patients who did not undergo resection, what was the fate of the adrenal mass? Were you able to document complete resolution? And, if not, was there a size reduction in the tumors?
What are your thoughts concerning the workup of these patients or the initial diagnostic evaluation with reference to the adrenocortical tumors that were identified?
Further, you hypothesized, and rightly so, in the discussion that all noninvasive loco-regional tumors might be amenable to observation. In that situation, would you recommend biopsy? And how would you change the diagnostic parameters?
CLOSING DISCUSSANT
DR. JED G. NUCHTERN: First of all, in fact, more than half of patients had a small residual mass at the end of observation. We recommended that any mass over 2 ml be resected. But this was not a requirement. In general, the patients did not have those resections done.
The patients are followed for ten years on this study. We will be looking for any evidence of progression in those patients, and that would be reported.
As far as extending the study to older patients with larger masses, we feel that it would be safe to observe those patients without a biopsy. However, we do feel --and this gets at your second question also --we do feel it would be important in some of way to prove they are neuroblastomas, thus we are going to require that they either be MIBG positive or have some other evidence to prove that they are neuroblastoma.
The two adrenocortical tumors were very low grade. Neither one was actually called carcinoma on the path report. We really just don't have enough data about this entity in infants, so we'll have to continue to follow those patients.
DISCUSSANT
DR. THOMAS F. TRACY JR.: (Providence, RI): Getting back to Mike's question about enrolling a group of patients in this large study, it's surprising that you were able to have 84 that elected observation. So can you give us some details about how you set up your informed consent to discuss with these parents and these families about the data set from which you were able to offer observation as a treatment, and how that affected their enrollment?
And for the 16 patients that I saw that went to resection, it's very clear from the seven of those that had indications for exploration of either increased tumor volume or increased catecholamines. But the others were a mixed bag of the adrenal tumors, hemorrhage, and other factors, what were the drivers to get those patients into the operating room? None of them would have their outcomes affected other than the questionable adrenal tumors, the other pathology that you found.
So what within the protocol or within these centers pushed those infants into the operating room?
And finally, related to your comment that you just made about determining what these lesions are when they are imaged initially and the need to define them as neuroblastomas, do you really think that's necessary since all of these patients, even the ones that had relatively benign pathologies, did very well and would have done well without any diagnostic intervention other than catecholamines and the imaging that got them into the study?
CLOSING DISCUSSANT
DR. JED G. NUCHTERN: To address your first question about what data we use to explain the consent process and explain the disease process to parents, primarily, we relied on the extensive data from Japan, which clearly showed that this is a benign entity. And again, they had some prospective single-institution trials which have proved it, although most of those trials weren't done when the study was designed. We also looked at single-institution studies from the U.S. and Europe which showed that small groups of patients could be watched safely.
As far as what drove the other patients to the OR, we assumed that all these patients were neuroblastomas. And so the two adrenocortical tumors grew, they achieved a greater than 50% increase in volume, and that's why they were resected. One of the sequestrations grew. And one of the hemorrhages had biochemical signs of a dedifferentiating neuroblastoma. And then the other two just were at parent request; they decided that they didn't want to watch it anymore.
I think it's a valid question, whether or not we really have to prove these are neuroblastomas or not to extend the eligibility criteria. Forgive the pun, but we generally take baby steps in the Children's Oncology Group. So they hold themselves to a very high level of safety, which I think is very appropriate. That was part of the requirements of the Scientific Council. First, most of these tumors are very discrete and encapsulated. How many of them were resected laparoscopically?
The second question is your diagnostic strategy. As you followed these, and there is often parental anxiety and difficulty seeing them with ultrasound, how many of these children got CAT scans? So would you trade expectant observation for four or five CAT scans in a radiosensitive infant?
DR. JED G. NUCHTERN: To address your second question first, I think that's an extremely good point. And again, you have to put yourself back to 2000, when our sensitivity about performing CT scans in infants was much less developed. Dr. Shamberger and I really did not want to have CT scan in the study. But again, the COG Scientific Council felt that that was the safe way to go. I think, in 2012 and 2013, you can very legitimately ask whether or not that's justified, and even whether general anesthesia to perform an MRI, for example, is justified. I think our study provides reassurance that it's really not necessary. In fact, none of the patients who had a neuroblastoma event was it picked up on cross-sectional imaging. The one patient who developed liver involvement was picked up on an ultrasound. It was the first ultrasound after enrollment.
As far as the number of laparoscopic resections, I can't tell you the exact number. It was very low. There may have been one or two. 
DR. JED G. NUCHTERN: It's interesting, because we assumed that the cystic neuroblastomas would be more likely to regress because they were more like the fetal type of neuroblastoma. And we did, in fact, notice that there seemed to be a trend towards that taking place, but it wasn't statistically significant.
As far as the thoracic neuroblastomas go, it actually turns out that if you look at the probability of a neuroblastoma in an infant regressing, this is in six-month-old infants, and this data is from Japan, in fact, a nonadrenal neuroblastoma is statistically more likely to regress than an adrenal neuroblastoma. So I would say that for a patient with a thoracic neuroblastoma, I would feel even more comfortable observing that infant than an adrenal one. One of the other ways we are going to extend the study is to allow other sites.
DISCUSSANT
DR. JOHN HOLCOMB (Houston, TX): The 11 patients who were lost to follow-up would be a significant concern in most other studies, with statisticians and DSMBs considering those patients counted as fatalities. How did you handle this with your DSMB and your statistical analysis?
CLOSING DISCUSSANT
DR. JED G. NUCHTERN: It's a little difficult for me to answer that because the Data Safety Monitoring Board never did raise any problem with that. You have to remember that we are dealing with young families who have been somewhat reassured that the mass is likely to regress, and they move around a lot. They leave the city. They lose their insurance. Various things happen that prevent them from following up and prevent them from completing this period of observation.
So I think it's a very good point, but I think that the data is still valid as far as we stated.
